* Pharvaris NV PHVS.OQ PHVS.O is expected to show no
change in
quarterly revenue when it reports results on May 6 (estimated)
for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Pharvaris NV is for a
loss
of 56 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pharvaris
NV is
$35.00, above its last closing price of $23.53.
Previous quarterly performance (using preferred earnings measure
in euros).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.37 -0.53 -0.76 Missed -42.5
Jan. 1 0001 -0.59 -0.60 -0.58 Beat 3.4
Jun. 30 2023 -0.59 -0.65 -0.63 Beat 3.1
Jan. 1 0001 -0.74 -0.74 -0.67 Beat
Dec. -0.68 -0.65 -1.17 Missed -79.4
31 2022
Jan. 1 0001 -0.63 -0.63 -0.25 Beat 60.5
Jun. 30 2022 -0.57 -0.56 -0.38 Beat 31.8
Jan. 1 0001 -0.43 -0.48 2.7
This summary was machine generated May 3 at 11:05 GMT. All
figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)